1,333 results on '"Inwards, David"'
Search Results
152. Long-Term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-Cda) Alone (95-80-53) Or 2-Cda and Rituximab (N0189) in the North Central Cancer Treatment Group
153. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
154. Host Genetic Variation in the TNF and NF-ĸB Pathways and Overall Survival in Mantle Cell Lymphoma: A Discovery and Replication Study
155. Immune reconstitution after autologous hematopoietic transplantation with Lin−, CD34+, Thy-1lo selected or intact stem cell products
156. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas
157. AMD3100 Affects Autograft Lymphocyte Collection and Progression-Free Survival After Autologous Stem Cell Transplantion in Non-Hodgkin Lymphoma
158. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma
159. Combined positron emission tomography/computed tomography for evaluation of presumed choroidal metastases
160. Absolute lymphocyte count predicts overall survival in follicular lymphomas
161. Response to Rituximab in Patients with Type II Cryoglobulinemia
162. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
163. Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation
164. Primary Lymphomas of Bone
165. Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
166. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
167. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
168. Therapeutic Options in Patients With Lymphoma and Severe Liver Dysfunction
169. Posttransplantation Thrombotic Thrombocytopenic Purpura: A Single-Center Experience and a Contemporary Review
170. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease
171. Autologous Transplantation for Aggressive Non-Hodgkin’s Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease
172. Stem cell transplantation for the management of primary systemic amyloidosis
173. Fatal Disseminated Aspergillosis following Sequential Heart and Stem Cell Transplantation for Systemic Amyloidosis
174. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
175. Acquired C1 Esterase Inhibitor Deficiency
176. A Randomized, Placebo-Controlled Study of Outpatient Premedication for Bone Marrow Biopsy in Adults with Lymphoma
177. Testicular lymphoma is associated with a high incidence of extranodal recurrence
178. Impact of MYD88 L265P mutation status on histological transformation of Waldenström Macroglobulinemia
179. Central Nervous System Involvement in Peripheral T-Cell Lymphoma
180. Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma
181. Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
182. Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era
183. Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
184. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes
185. Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).
186. Outcomes of stem cell transplant in patients with Richter transformation.
187. Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.
188. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation
189. Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study
190. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
191. Spontaneous Remission of Anemia Associated with a Myelodysplastic Syndrome with Disease Evolution into a Myeloproliferative State
192. Granulomatous Vasculitis Associated With Herpes Virus
193. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation
194. Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis.
195. Refractory and Relapsing Multiple Myeloma Treated by Blood Stem Cell Transplantation
196. 27-Year-Old Woman With Pancytopenia
197. Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
198. Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
199. Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
200. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.